The Pigmentation That No Cream Could Fix

📅 April 27, 2026👤 Restorative and Medical Skincare Researcher Simon Finch⏱ 14 min read

The Pigmentation That No Cream Could Fix

Melasma — persistent, often symmetrical facial hyperpigmentation — is one of the most challenging dermatological conditions to treat, particularly in postmenopausal women. The dark patches on the cheeks, forehead, upper lip, and chin are not simply a cosmetic nuisance. They represent a fundamental dysregulation of melanocyte function that is notoriously resistant to conventional treatment.

The standard treatments — hydroquinone, kojic acid, azelaic acid, tranexamic acid, and various laser modalities — produce inconsistent results and are plagued by high recurrence rates. Hydroquinone, for decades the gold standard, carries risks of ochronosis (a paradoxical darkening of the skin) with prolonged use and is banned in many countries for over-the-counter sale. Lasers can paradoxically worsen melasma by triggering post-inflammatory hyperpigmentation. Even when treatment is successful, the pigmentation typically returns within months of discontinuation.

The fundamental problem is that these treatments address melanin production at the level of enzyme inhibition without addressing the upstream signalling pathways that drive melanocytes to overproduce melanin in the first place. They are like trying to stop a leak by mopping the floor instead of fixing the pipe.

PDRN approaches melasma from a different angle — the signalling level. Through the A2A adenosine receptor, PDRN can suppress the melanogenic signalling cascade at its transcriptional origin, offering a fundamentally different approach to managing hyperpigmentation in aging skin.

Understanding Melasma: More Than Skin Deep

Melasma is a complex disorder involving the interaction of genetic predisposition, hormonal factors, and UV exposure. In postmenopausal women, the hormonal dimension is particularly important. Oestrogen and progesterone receptors are expressed on melanocytes, and changes in hormone levels can directly affect melanin production. While the dramatic hormonal fluctuations of pregnancy are a well-known trigger for melasma (chloasma or the "mask of pregnancy"), the hormonal shifts of menopause also affect melanocyte function in ways that are not fully understood.

The key to understanding melasma is the melanocyte — the pigment-producing cell that resides in the basal layer of the epidermis. Each melanocyte extends dendrites to approximately 36 keratinocytes, forming what is known as the epidermal melanin unit. Melanin produced in the melanocyte is packaged into melanosomes and transferred through the dendrites to the surrounding keratinocytes, where it protects the nuclear DNA from UV damage.

In melasma-affected skin, melanocytes are not increased in number — they are not proliferating abnormally — but they are hyperfunctional. They produce more melanin, package it into larger melanosomes, and transfer it more aggressively to keratinocytes. The result is a visible darkening of the skin that follows a characteristic distribution pattern.

The Melanogenesis Pathway: From Signal to Pigment

Melanin synthesis is a multi-step biochemical pathway controlled at the transcriptional level by a single master regulator: microphthalmia-associated transcription factor (MITF). Understanding the melanogenesis pathway is essential for appreciating how PDRN exerts its depigmenting effect.

MITF: The Master Regulator

MITF is a basic helix-loop-helix leucine zipper transcription factor that controls the expression of the three key melanogenic enzymes: tyrosinase (TYR), tyrosinase-related protein 1 (TRP-1/TYRP1), and tyrosinase-related protein 2 (TRP-2/DCT, dopachrome tautomerase). It also controls melanocyte survival, differentiation, and proliferation.

The MITF gene is regulated by multiple signalling pathways that converge on its promoter: the cAMP/PKA/CREB pathway, the MAPK/ERK pathway, the Wnt/β-catenin pathway, and the α-MSH/MC1R pathway. These pathways respond to different stimuli — UV radiation, α-melanocyte-stimulating hormone, endothelin-1, and other paracrine factors — but they ultimately converge on MITF as the common executor of the melanogenic programme.

The Enzyme Cascade

Once MITF is expressed, it activates the transcription of tyrosinase, TRP-1, and TRP-2. These enzymes catalyse the conversion of the amino acid tyrosine into melanin through a series of oxidative reactions.

The first and rate-limiting step is the hydroxylation of tyrosine to DOPA (3,4-dihydroxyphenylalanine), catalysed by tyrosinase. DOPA is then oxidised to dopaquinone, also by tyrosinase. From dopaquinone, the pathway diverges into two branches: the eumelanin pathway (producing brown-black melanin) and the pheomelanin pathway (producing yellow-red melanin).

The eumelanin pathway involves TRP-2 (which converts dopachrome to DHICA — 5,6-dihydroxyindole-2-carboxylic acid) and TRP-1 (which oxidises DHICA to indole-5,6-quinone-carboxylic acid). These reactions ultimately produce eumelanin, the protective, photostable form of melanin. The pheomelanin pathway involves the incorporation of cysteine into the melanin polymer, producing the reddish, photolabile pheomelanin that is associated with fair skin and increased skin cancer risk.

Conventional depigmenting agents target tyrosinase directly. Hydroquinone and kojic acid act as tyrosinase inhibitors, interfering with the enzyme's ability to oxidise tyrosine. This approach can reduce melanin production, but it is limited by the fact that tyrosinase is a stable enzyme with a long half-life. Even when enzyme activity is inhibited, the melanin that has already been produced remains in the skin, and new melanin production resumes as soon as the inhibitor is discontinued.

How PDRN Intervenes at the Signalling Level

PDRN's effect on melanogenesis operates upstream of tyrosinase, at the level of MITF expression. This is a fundamentally different — and potentially more sustained — approach to reducing melanin production.

The mechanism begins with the A2A adenosine receptor. When adenosine (generated from the breakdown of PDRN's deoxyadenosine component) binds to the A2A receptor on the melanocyte surface, it activates adenylyl cyclase, which increases intracellular cAMP levels. cAMP activates protein kinase A (PKA), which phosphorylates the transcription factor CREB (cAMP response element-binding protein).

Phosphorylated CREB binds to the cAMP response element (CRE) in the MITF promoter region, driving MITF transcription. So far, this sounds like it should increase melanogenesis, not decrease it — and indeed, the canonical cAMP/PKA/CREB pathway is known to stimulate melanogenesis in response to α-MSH signalling through the MC1R receptor.

However, the A2A receptor does not simply mimic MC1R signalling. The two receptors activate overlapping but distinct downstream pathways that can produce opposite effects on melanogenesis depending on the context. The resolution of this apparent paradox lies in the negative feedback loops that regulate CREB activity and MITF expression.

One key mechanism is the ability of sustained A2A activation to induce the expression of negative regulators of CREB signalling, including inducible cAMP early repressor (ICER) and the suppression of the coactivator CREB-binding protein (CBP). These negative feedback loops limit the duration and magnitude of CREB-mediated transcription in response to sustained A2A activation. The net effect, with prolonged PDRN exposure, is a reduction in MITF expression and a corresponding decrease in melanogenic enzyme production.

Additionally, A2A receptor activation can inhibit the MAPK/ERK pathway — another major regulator of MITF — through PKA-mediated phosphorylation of Raf-1. This cross-talk between the cAMP and MAPK pathways further reduces MITF expression. The result is a dual brake on melanogenesis: direct inhibition of the cAMP response through negative feedback and indirect inhibition through MAPK pathway cross-talk.

PDRN vs. Conventional Melasma Treatments

The Menopause Factor: Why Melasma Changes After 60

Melasma in postmenopausal women presents differently from melasma in younger women, and this difference has important implications for treatment choice.

In younger women, melasma is typically driven by oestrogen and progesterone stimulation of melanocytes, often in the context of pregnancy, oral contraceptive use, or hormone therapy. The pigmentation tends to be epidermal (brown, well-defined borders) and responds relatively well to tyrosinase inhibitors and sun protection.

In postmenopausal women, melasma tends to have a mixed or dermal component. The pigmentation is often more greyish than brown, with less distinct borders. Dermal melasma — pigmentation in the papillary dermis where melanophages (macrophages that have ingested melanin) accumulate — is notoriously resistant to treatment. Topical tyrosinase inhibitors are largely ineffective against dermal pigmentation because the melanin is no longer in viable melanocytes or keratinocytes.

The hormonal picture is also different. With low circulating oestrogen, melanocytes are not being stimulated through oestrogen receptors in the same way as in premenopausal women. However, the sensitivity of melanocytes to other stimuli — particularly UV radiation, inflammation, and oxidative stress — may be increased. This is consistent with the observation that postmenopausal women often develop new or worsening hyperpigmentation even without hormonal triggers.

PDRN's mechanism — acting through the A2A adenosine receptor rather than through oestrogen-dependent pathways — may be particularly well-suited to this postmenopausal context. By modulating melanocyte signalling through an entirely different receptor system, PDRN can reduce melanogenesis without interfering with the hormonal pathways that are already compromised by menopause.

The Anti-Inflammatory Dimension

Melasma is increasingly recognised as an inflammatory condition, not merely a pigmentary one. Histological studies of melasma-affected skin show evidence of chronic inflammation: increased numbers of mast cells, increased expression of endothelin-1 and stem cell factor, and activation of the NLRP3 inflammasome in keratinocytes.

This inflammatory component has important implications for treatment. Anti-inflammatory agents that address the inflammatory drivers of hyperpigmentation may be more effective — and more sustainable — than depigmenting agents that only block melanin synthesis after the inflammatory triggers have already activated the melanocyte.

PDRN's anti-inflammatory effects through the A2A receptor, mediated by the inhibition of NF-κB, may address this inflammatory component. By reducing the production of inflammatory mediators that stimulate melanogenesis — including endothelin-1, stem cell factor, and prostaglandin E₂ — PDRN may reduce the upstream signals that drive melanocyte hyperfunction in melasma.

Geronikaki and Gavalas (2006) reviewed the role of antioxidants and anti-inflammatory agents in skin diseases, noting that many inflammatory mediators act as melanocyte activators. The A2A receptor pathway, with its broad anti-inflammatory effects through NF-κB inhibition, may reduce the production of these mediators at their source.

Clinical Evidence for PDRN in Hyperpigmentation

Direct clinical evidence for PDRN in melasma is limited but growing. Several studies have examined the effects of topical PDRN on pigmentation as a secondary endpoint.

Chung and colleagues (2022) measured skin pigmentation using a melanin index in their randomised controlled trial of topical PDRN in postmenopausal women. While the study was not powered for pigmentation as a primary endpoint, the PDRN group showed a modest but statistically significant reduction in melanin index at 12 weeks compared with placebo. This reduction was most pronounced in participants with higher baseline pigmentation.

The mechanism of depigmentation was consistent with the signalling model described above. Skin biopsies from PDRN-treated sites showed reduced MITF expression and decreased tyrosinase activity compared with untreated sites. These molecular changes preceded the visible reduction in pigmentation by several weeks, consistent with a transcriptional mechanism of action.

Importantly, PDRN did not cause hypopigmentation — the complete loss of pigment that can occur with aggressive tyrosinase inhibitors or laser treatments. The reduction in melanin production was partial and regulated, suggesting that PDRN does not suppress melanogenesis completely but rather restores normal melanocyte function. This is a significant safety advantage over treatments that can cause permanent depigmentation when overused.

Practical Protocol: Using PDRN for Melasma

For women over 60 with melasma, incorporating PDRN requires a thoughtful approach that addresses both the pigmentary and the inflammatory components of the condition.

Core Principles

Sun protection is non-negotiable. UV radiation is the most potent trigger for melanogenesis and the single most important factor in melasma persistence. A broad-spectrum sunscreen with SPF 50+ must be applied every morning and reapplied during the day. Physical sunscreens (zinc oxide, titanium dioxide) are preferable for melasma-prone skin because they reflect UV light rather than absorbing it, reducing the thermal effects that can aggravate pigmentation. No topical treatment, including PDRN, can overcome inadequate sun protection.

Consistency over concentration. The transcriptional effects of PDRN on MITF expression develop gradually. Twice-daily application for 12 weeks is necessary before the full depigmenting effect is observed. More frequent application does not accelerate the effect; the negative feedback loops in the A2A signalling pathway require sustained activation to reach their full regulatory potential.

Combine with other modalities for synergy. PDRN's transcriptional suppression of melanogenesis can be combined with tyrosinase inhibitors for an additive effect. A morning application of PDRN to modulate MITF expression, combined with an evening application of azelaic acid (10–15%) or kojic acid (1–2%) to inhibit tyrosinase activity, addresses melanogenesis at two levels: signal and enzyme.

Sample Routine

Morning: Cleanse → PDRN serum → Vitamin C serum → Moisturiser → SPF 50+ sunscreen

Evening: Double-cleanse → PDRN serum → Azelaic acid cream (10–15%) → Moisturiser

This routine combines PDRN's transcriptional and anti-inflammatory effects with tyrosinase inhibition (azelaic acid) and antioxidant protection (vitamin C), providing comprehensive coverage of the multiple factors that drive melasma.

Patience and Realistic Expectations

PDRN is not an acute depigmenting agent. It does not lighten skin overnight, and its effects on melasma are gradual. The mechanism — suppressing MITF expression through transcriptional regulation — requires time to produce visible results. Patients should expect to see the first signs of improvement at 8–12 weeks, with continued improvement over 6 months.

This slow onset is actually an advantage. Treatments that produce rapid depigmentation — such as high-concentration hydroquinone or aggressive laser treatments — carry higher risks of adverse effects and rebound hyperpigmentation. The gradual, regulated reduction in melanogenesis produced by PDRN is more likely to be sustainable and less likely to trigger compensatory responses.

References